Swedish Orphan Biovitrum AB (OSTO:SOBI) Accounts Payable & Accrued Expense : kr671 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Accounts Payable & Accrued Expense?

Swedish Orphan Biovitrum AB's quarterly accounts payable & accrued expense increased from Sep. 2023 (kr1,055 Mil) to Dec. 2023 (kr1,326 Mil) but then declined from Dec. 2023 (kr1,326 Mil) to Mar. 2024 (kr671 Mil).

Swedish Orphan Biovitrum AB's annual accounts payable & accrued expense increased from Dec. 2021 (kr862 Mil) to Dec. 2022 (kr1,636 Mil) but then declined from Dec. 2022 (kr1,636 Mil) to Dec. 2023 (kr1,326 Mil).

Swedish Orphan Biovitrum AB Accounts Payable & Accrued Expense Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Accounts Payable & Accrued Expense Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,356.00

1,409.00

862.00

1,636.00

1,326.00

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															625.00	933.00	1,055.00	1,326.00	671.00

Swedish Orphan Biovitrum AB Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines